| Published Application/Species/Sample/Dilution | Reference |
|---|
- ELISA; mouse; 125 ng/ml; loading ...; fig 4b
| Zeitler B, Froelich S, Marlen K, Shivak D, Yu Q, Li D, et al. Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease. Nat Med. 2019;25:1131-1142 pubmed publisher |
- western blot; mouse; 1:1000; loading ...; fig 2c
- western blot; human; 1:1000; loading ...; fig 1d
| Rue L, Bañez Coronel M, Creus Muncunill J, Giralt A, Alcalá Vida R, Mentxaka G, et al. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels. J Clin Invest. 2016;126:4319-4330 pubmed publisher |
- western blot; mouse; 1:100
| O Brien R, DeGiacomo F, Holcomb J, Bonner A, Ring K, Zhang N, et al. Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo. J Biol Chem. 2015;290:19287-306 pubmed publisher |
- immunohistochemistry - paraffin section; mouse; 1:500
| Blum D, Herrera F, Francelle L, Mendes T, Basquin M, Obriot H, et al. Mutant huntingtin alters Tau phosphorylation and subcellular distribution. Hum Mol Genet. 2015;24:76-85 pubmed publisher |
- immunohistochemistry; rat
- western blot; rat
| Haun F, Nakamura T, Shiu A, Cho D, Tsunemi T, Holland E, et al. S-nitrosylation of dynamin-related protein 1 mediates mutant huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington's disease. Antioxid Redox Signal. 2013;19:1173-84 pubmed publisher |
- immunohistochemistry - free floating section; rat; 1:100
- immunocytochemistry; rat; 1:50
- western blot; rat; 1:2500
| Taylor D, Moser R, Regulier E, Breuillaud L, Dixon M, Beesen A, et al. MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition. J Neurosci. 2013;33:2313-25 pubmed publisher |
| Huang T, Smith R, Bacos K, Song D, Faull R, Waldvogel H, et al. No symphony without bassoon and piccolo: changes in synaptic active zone proteins in Huntington's disease. Acta Neuropathol Commun. 2020;8:77 pubmed publisher |
| Al Dalahmah O, Sosunov A, Shaik A, Ofori K, Liu Y, Vonsattel J, et al. Single-nucleus RNA-seq identifies Huntington disease astrocyte states. Acta Neuropathol Commun. 2020;8:19 pubmed publisher |
| Long J, Idoko Akoh A, Mistry B, Goldhill D, Staller E, Schreyer J, et al. Species specific differences in use of ANP32 proteins by influenza A virus. elife. 2019;8: pubmed publisher |
| Ochaba J, Fote G, Kachemov M, Thein S, Yeung S, Lau A, et al. IKKβ slows Huntington's disease progression in R6/1 mice. Proc Natl Acad Sci U S A. 2019;116:10952-10961 pubmed publisher |
| Deguire S, Ruggeri F, Fares M, Chiki A, Cendrowska U, Dietler G, et al. N-terminal Huntingtin (Htt) phosphorylation is a molecular switch regulating Htt aggregation, helical conformation, internalization, and nuclear targeting. J Biol Chem. 2018;293:18540-18558 pubmed publisher |
| Pan Y, Zhu Y, Yang W, Tycksen E, Liu S, Palucki J, et al. The role of Twist1 in mutant huntingtin-induced transcriptional alterations and neurotoxicity. J Biol Chem. 2018;293:11850-11866 pubmed publisher |
| Al Ramahi I, Giridharan S, Chen Y, Patnaik S, Safren N, Hasegawa J, et al. Inhibition of PIP4K? ameliorates the pathological effects of mutant huntingtin protein. elife. 2017;6: pubmed publisher |
| Grima J, Daigle J, Arbez N, Cunningham K, Zhang K, Ochaba J, et al. Mutant Huntingtin Disrupts the Nuclear Pore Complex. Neuron. 2017;94:93-107.e6 pubmed publisher |
| Vieweg S, Ansaloni A, Wang Z, Warner J, Lashuel H. An Intein-based Strategy for the Production of Tag-free Huntingtin Exon 1 Proteins Enables New Insights into the Polyglutamine Dependence of Httex1 Aggregation and Fibril Formation. J Biol Chem. 2016;291:12074-86 pubmed publisher |
| Gu X, Cantle J, Greiner E, Lee C, Barth A, Gao F, et al. N17 Modifies mutant Huntingtin nuclear pathogenesis and severity of disease in HD BAC transgenic mice. Neuron. 2015;85:726-41 pubmed publisher |
| Schut M, Pepers B, Klooster R, van der Maarel S, El Khatabi M, Verrips T, et al. Selection and characterization of llama single domain antibodies against N-terminal huntingtin. Neurol Sci. 2015;36:429-34 pubmed publisher |
| Yano H, Baranov S, Baranova O, Kim J, Pan Y, Yablonska S, et al. Inhibition of mitochondrial protein import by mutant huntingtin. Nat Neurosci. 2014;17:822-31 pubmed publisher |
| Watkin E, Arbez N, Waldron Roby E, O Meally R, Ratovitski T, Cole R, et al. Phosphorylation of mutant huntingtin at serine 116 modulates neuronal toxicity. PLoS ONE. 2014;9:e88284 pubmed publisher |
| Ansaloni A, Wang Z, Jeong J, Ruggeri F, Dietler G, Lashuel H. One-pot semisynthesis of exon 1 of the Huntingtin protein: new tools for elucidating the role of posttranslational modifications in the pathogenesis of Huntington's disease. Angew Chem Int Ed Engl. 2014;53:1928-33 pubmed publisher |
| Jovicic A, Zaldivar Jolissaint J, Moser R, Silva Santos M, Luthi Carter R. MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms. PLoS ONE. 2013;8:e54222 pubmed publisher |
| Dong X, Zong S, Witting A, Lindenberg K, Kochanek S, Huang B. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration. J Gene Med. 2012;14:468-81 pubmed publisher |
| Jeong H, Cohen D, Cui L, Supinski A, Savas J, Mazzulli J, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med. 2011;18:159-65 pubmed publisher |
| Seredenina T, Gokce O, Luthi Carter R. Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation. PLoS ONE. 2011;6:e22231 pubmed publisher |
| Fox J, Connor T, Stiles M, Kama J, Lu Z, Dorsey K, et al. Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein. J Biol Chem. 2011;286:18320-30 pubmed publisher |
| Tang B, Seredenina T, Coppola G, Kuhn A, Geschwind D, Luthi Carter R, et al. Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease. Neurobiol Dis. 2011;42:459-67 pubmed publisher |
| Fox J, Connor T, Chopra V, Dorsey K, Kama J, Bleckmann D, et al. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. Mol Neurodegener. 2010;5:26 pubmed publisher |
| Jeong H, Then F, Melia T, Mazzulli J, Cui L, Savas J, et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell. 2009;137:60-72 pubmed publisher |
| Ermak G, Hench K, Chang K, Sachdev S, Davies K. Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro. J Biol Chem. 2009;284:11845-53 pubmed publisher |
| Huang B, Schiefer J, Sass C, Kosinski C, Kochanek S. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion. J Gene Med. 2008;10:269-79 pubmed |
